LEF1-AS1: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

Target Name: LEF1-AS1

NCBI ID: G641518

LEF1-AS1

Other Name(s): LEF1NAT | LEF1 antisense RNA 1 | LEF1-AS1 variant 1

LEF1-AS1: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

LEF1-AS1, also known as LEF1NAT, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the LEF1 family of proteins, which are known for their role in cell signaling and division. LEF1-AS1 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, it has become a focus of interest for researchers looking for new treatments and biomarkers.

The LEF1 family of proteins was identified through studies of the gene LEF1, which is located on chromosome 18 and has been implicated in the development of many diseases, including cancer. The LEF1 gene is encoding a 21 kDa polypeptide chain that includes a An alpha helix, a beta sheet, and a gamma helix. 伪-helix and 尾-sheet are the most conserved structural units in proteins, while 纬-helix is 鈥嬧?媟elatively unstable. The polypeptide chain encoded by the LEF1 gene contains an N-terminal 伪-helix, two C-terminal 尾-sheets, and a central 纬-helix. In addition, the LEF1 gene also encodes a modified N-terminal 伪-helix, which can increase protein stability.

During the occurrence and development of tumors, changes in LEF1 gene expression levels have always attracted much attention. Studies have shown that LEF1 gene expression levels are up-regulated in a variety of tumors, including lung cancer, liver cancer, breast cancer, etc. In addition, LEF1 gene expression levels are also related to tumor invasion and metastasis capabilities. Therefore, the LEF1 gene is considered a potential tumor treatment target.

LEF1-AS1 is a protein originally discovered on human chromosome 18. It is a dimer composed of two subunits, each subunit containing an 伪-helix, a 尾-sheet and a 纬-helix. LEF1-AS1 has a wide range of biological functions, including roles in cell proliferation, differentiation, and tumorigenesis. LEF1-AS1 is considered a therapeutic target in a variety of diseases.

In cancer research, LEF1-AS1 is used as a therapeutic target, particularly for treating neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. Studies have shown that silencing of LEF1-AS1 is associated with the onset and progression of neurodegenerative diseases. Therefore, LEF1-AS1 is considered a potential therapeutic target for these diseases.

In addition, LEF1-AS1 is also used as a biomarker to study the molecular mechanisms of neurodegenerative diseases. Studies have shown that LEF1-AS1 can serve as an important biomarker for neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. In addition, LEF1-AS1 can also serve as a therapeutic target for other neurodegenerative diseases, such as lateral sclerosis and multiple sclerosis.

In summary, LEF1-AS1 is a protein with important biological functions and has broad application value in tumor occurrence and development, neurodegenerative diseases, and other diseases. Therefore, LEF1-AS1 is a potential drug target and an important biomarker for studying neurodegenerative diseases. Future research will focus on the role of LEF1-AS1 in drug screening and therapeutic targets, with a view to bringing more help to human health.

Protein Name: LEF1 Antisense RNA 1

The "LEF1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LEF1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets